Chemotherapy is the use of cytotoxic drugs to kill cancer cells or halt their proliferation, and it remains a cornerstone of treatment across hematology and oncology. These agents act preferentially on rapidly dividing cells, a hallmark of malignancy, and may be given orally or by intravenous infusion, alone or in c…
Chemotherapy is the use of cytotoxic drugs to kill cancer cells or halt their proliferation, and it remains a cornerstone of treatment across hematology and oncology. These agents act preferentially on rapidly dividing cells, a hallmark of malignancy, and may be given orally or by intravenous infusion, alone or in combination regimens and alongside radiotherapy, surgery, or stem-cell transplantation. Because chemotherapy also affects healthy fast-dividing tissues, it carries characteristic toxicities, including suppression of blood-cell production, that must be managed during care. Peer-reviewed research indexed here illustrates the breadth of this field: case-based work has described progressive multifocal leukoencephalopathy arising during R-CHOP chemotherapy in lymphoma, and studies have evaluated plerixafor for rescue mobilization of autologous peripheral blood stem cells, a step often required before high-dose chemotherapy. Other indexed work has investigated lineage-specific disruption of hematopoiesis by oxaliplatin, examining mechanisms of erythropoietin resistance and immune suppression that contribute to chemotherapy-related cytopenias. Together these reflect both the therapeutic role and the hematologic consequences of cytotoxic treatment. This page collects open-access, peer-reviewed research relevant to chemotherapy in Hematology and Oncology Research.
12 peer-reviewed articles, ranked by relevance. Each links to its DOI.
The 12 articles above have been cited 22 times in the scholarly literature. Citation data via OpenAlex and Crossref, updated Jun 2026.
A sample of recent works citing this journal's research on Chemotherapy, linking to each citing work.